# A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

> **NCT05362773** · PHASE1 · RECRUITING · sponsor: **MacroGenics** · enrollment: 130 (estimated)

## Conditions studied

- Leukemia, Acute Myeloid
- Myelodysplastic Syndromes
- Classical Hodgkin Lymphoma
- Leukemia, B-cell
- Leukemia, Hairy Cell
- Mastocytosis, Aggressive Systemic
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** MGD024

## Key facts

- **NCT ID:** NCT05362773
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2026-11
- **Final completion:** 2027-05
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05362773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05362773, "A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05362773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*